<?xml version="1.0" encoding="utf-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
<!--  created with Free Online XML Sitemap Generator http://www.seocert.net/xml-sitemap-generator.php -->
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/informasjon-om-innsending-av-soknader-og-saksbehandlingstid-ved-godkjenningsfritak</loc><changefreq>daily</changefreq><priority>1.00</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om</loc><changefreq>daily</changefreq><priority>1.00</priority></url>
<url><loc>http://www.legemiddelverket.no/innhold-a-a</loc><changefreq>daily</changefreq><priority>1.00</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss</loc><changefreq>daily</changefreq><priority>1.00</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/programvare-som-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.75</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/meld-bivirkninger</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/veiledning-og-regelverk</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/hendelser-og-sikkerhetstiltak</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/for-helsetjenesten</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/klinisk-utproving-av-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering</loc><changefreq>daily</changefreq><priority>0.51</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/desinfeksjonsmidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/legemidler-mot-covid-19</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/offentlig-finansiering-av-legemidler-og-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/bivirkningsmelding-for-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/legemiddelovervaking</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-pasienter</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/interaksjonsdata-fra-dmp</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/varsler-fra-dmp</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-leger-og-tannleger</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-leger-og-tannleger/rutine-for-godkjenningsfritak-ved-sykehus</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-leger-og-tannleger/legemidler-det-ofte-er-sporsmal-om-ved-godkjenningsfritak</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-apotek</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-apotek/hvilke-legemidler-kan-notifiseres-og-hvilke-ma-vurderes-av-dmp-for-utlevering</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/informasjon-for-firmaer-som-onsker-a-markedsfore-legemidler-som-tas-inn-via-godkjenningsfritak</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/arsrapporter-om-godkjenningsfritak</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/forsyningssikkerhet-og-beredskap</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/eudamed</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anmodning-og-forslag</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/pris-pa-legemidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/medisinbytte-i-apotek</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/refusjonslisten-refusjonssok</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/endringer-i-refusjon-av-diabeteslegemidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekokonomi</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/avgifter</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/narkotika-og-doping</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/salg-utenom-apotek</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/sikkerhetsanordninger-for-legemidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/legemiddelstatistikk</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/utlevering-og-salg-i-apotek</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/mangel-pa-veterinere-legemidler</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/fisk</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/nytt-om-veterinere-legemidler-vet-nyl</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/regelverk-for-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/salg-import-og-innforsel-av-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/blodgivning-og-transfusjonsmedisin</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/ny-soho-forordning-fra-2027</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>http://www.legemiddelverket.no/skjemaer</loc><changefreq>daily</changefreq><priority>0.50</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/who-sertifikater</loc><changefreq>daily</changefreq><priority>0.44</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/ocabr-av-blodprodukter-og-vaksiner-til-mennesker</loc><changefreq>daily</changefreq><priority>0.44</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/hvem-skal-du-kontakte-i-regulatoriske-sporsmal</loc><changefreq>daily</changefreq><priority>0.43</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon</loc><changefreq>daily</changefreq><priority>0.43</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler/forpliktelser-etter-utstedelse-av-markedsforingstillatelse-for-parallellimportert-legemiddel</loc><changefreq>daily</changefreq><priority>0.42</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler</loc><changefreq>daily</changefreq><priority>0.42</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler/soknad-om-markedsforingstillatelse-for-parallellimportert-legemiddel</loc><changefreq>daily</changefreq><priority>0.42</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/endringer-fornyelse-tilbakekallelse-og-bortfall-av-registrering-av-homoopatiske-legemidler</loc><changefreq>daily</changefreq><priority>0.41</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/soknad-om-registrering-av-homoopatisk-legemiddel-til-dyr</loc><changefreq>daily</changefreq><priority>0.41</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/soknad-om-registrering-av-homoopatisk-legemiddel-til-mennesker</loc><changefreq>daily</changefreq><priority>0.40</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/liste-over-homoopatiske-legemidler-tillatt-omsatt-i-norge-fra-1.-juli-2017</loc><changefreq>daily</changefreq><priority>0.39</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/krav-om-registrering-av-homoopatiske-legemidler</loc><changefreq>daily</changefreq><priority>0.39</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler</loc><changefreq>daily</changefreq><priority>0.38</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/definisjoner-og-markedsadgang-for-plantebaserte-legemidler</loc><changefreq>daily</changefreq><priority>0.38</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/markedsforingstillatelse-for-naturlegemidler</loc><changefreq>daily</changefreq><priority>0.37</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/plantebaserte-legemidler-europeisk-regelverk-monografier-og-liste</loc><changefreq>daily</changefreq><priority>0.37</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/plantebaserte-legemidler-med-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.36</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/sporsmal-og-svar-om-markedsforingstillatelse-for-plantebaserte-legemidler</loc><changefreq>daily</changefreq><priority>0.36</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/dokumentasjonskrav-ved-soknad-om-markedsforingstillatelse-for-plantebasert-legemiddel</loc><changefreq>daily</changefreq><priority>0.35</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler</loc><changefreq>daily</changefreq><priority>0.35</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/harmonisering-av-pakningsvedlegg-og-merking-for-otc-legemidler-med-virkestoffrapport</loc><changefreq>daily</changefreq><priority>0.34</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/soknad-om-otc-status-og-endring-i-otc-status</loc><changefreq>daily</changefreq><priority>0.34</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/virkestoffrapporter</loc><changefreq>daily</changefreq><priority>0.33</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc</loc><changefreq>daily</changefreq><priority>0.33</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/lesbarhetstesting-og-bridging</loc><changefreq>daily</changefreq><priority>0.32</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/varseltrekantordningen-regulatorisk-informasjon</loc><changefreq>daily</changefreq><priority>0.32</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/anbefalinger-etter-psur-single-assessment-psusa</loc><changefreq>daily</changefreq><priority>0.31</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/anbefalinger-etter-referral-vedtatt-av-den-europeiske-kommisjonen</loc><changefreq>daily</changefreq><priority>0.31</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/anbefalinger-fra-prac-etter-referral-med-cmdh-konsensus</loc><changefreq>daily</changefreq><priority>0.30</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/anbefalinger-fra-prac-etter-utredning-av-signaler</loc><changefreq>daily</changefreq><priority>0.30</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon</loc><changefreq>daily</changefreq><priority>0.29</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/oppdateringer-som-folge-av-paediatric-regulation-art-45-og-46-arbeidsdeling-worksharing</loc><changefreq>daily</changefreq><priority>0.29</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/soknad-om-batchspesifikke-unntak-relatert-til-produktinformasjon</loc><changefreq>daily</changefreq><priority>0.29</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg</loc><changefreq>daily</changefreq><priority>0.28</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-merking-</loc><changefreq>daily</changefreq><priority>0.28</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/templater-veiledninger</loc><changefreq>daily</changefreq><priority>0.27</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/digitalt-pakningsvedlegg</loc><changefreq>daily</changefreq><priority>0.27</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/pris-pa-legemidler/maksimalpris</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/tiltak-ved-kvalitetssvikt-pa-legemidler</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/om-dmp.no/registrering-for-epost-varsel</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/eudamed/registrering-som-aktor</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/fullforte-metodevurderinger-for-legemidler</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/medisinbytte-i-apotek/byttelisten</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/kontaktinformasjon</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/ledige-stillinger</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-preparatomtale-og-pakningsvedlegg/internasjonale-enheter-ie-og-enhet-e-har-ulik-betydning</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/informasjon-for-legemiddelfirma/innsending-av-melding-om-legemiddelmangel</loc><changefreq>daily</changefreq><priority>0.26</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-preparatomtale-og-pakningsvedlegg</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/definisjon-pa-ulike-typer-legemiddel</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/informasjon-om-cannabidiol-cbd-for-virksomheter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/standardbetegenlser-standard-terms-med-henvisninger-til-rmsspor</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/meld-bivirkninger/bivirkningsmelding-for-pasienter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/meld-bivirkninger/bivirkningsmelding-helsepersonell</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/retningslinjer-for-utarbeidelse-og-distribusjon-av-oppleringsmateriell</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/kjere-helsepersonell-brev-med-sikkerhetsinformasjon-veiledning-for-innsending</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/medisinbytte-i-apotek/hva-er-byttbare-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/import-av-legemidler/innforselimport-av-legemidler-til-kliniske-studier-i-norge</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/retningslinjer-for-ommerking-av-utprovingspreparat-med-ny-haldbarhetsdato</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/desinfeksjonsmidler/veiledning-om-godkjenning-av-desinfeksjonsmidler-til-teknisk-bruk-i-helse-og-sykepleie</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/desinfeksjonsmidler/veiledning-om-godkjenning-av-desinfeksjonsmidler-til-teknisk-bruk-i-akvakulturanlegg-med-videre</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/avansert-terapi</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/cbd--hva-er-det-og-hva-sier-regelverket</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/klassifisering-ved-import-og-salg-er-produktet-mitt-et-legemiddel-</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/hvordan-tolke-klassifiseringsvedtak</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/klassifisering-av-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/medisinske-pastander</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/produktspesifikke-veiledere-om-klassifisering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/produktspesifikke-veiledere-om-klassifisering/fmt--fekal-mikrobiota-transplantasjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/produktspesifikke-veiledere-om-klassifisering/klassifisering-av-melatonin</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/produktspesifikke-veiledere-om-klassifisering/klassifisering-av-gassprodukter-til-medisinsk-bruk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/produktspesifikke-veiledere-om-klassifisering/deoksykolsyre-til-injeksjon-for-fettfjerning-er-legemidler-ikke-kosmetikk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/legemidler-mot-covid-19/oversikt-over-koronavaksiner-som-er-godkjent-eller-under-godkjenning</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/legemidler-mot-covid-19/godkjenningsprosessen-for-koronavaksiner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/legemidler-mot-covid-19/godkjenningsprosessen-for-legemidler-mot-covid-19</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/om-publiseringer-i-nls-og-ph.-eur.-i-2024</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/om-publiseringer-i-nls-og-ph.-eur.-i-2024/abbrevations-and-symbols</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/om-publiseringer-i-nls-og-ph.-eur.-i-2024/nye-endrede-og-utgatte-titler-i-nls-2024</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/standarder-for-monografier-med-titler-farmakopenavn-pa-norsk-engelsk-og-latin</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/legemiddelformmonografier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/basic-dose-forms</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/generelle-monografier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/homoopatiske-preparater</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/legemiddelformer-utgatt-fra</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/monografipreparater</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/radioaktive-preparater</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/trader-til-medisinsk-bruk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/monografier-som-egne-lister/vaksinestandarder</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/Ph.-Eur.-monografier-i-NLS-database</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/databasen-for-monografier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/Standarder/referansestandarder</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/alminnelige-pabud</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/bruk-av-hjelpestoffer</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/hjelpepreparater</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/isotone-vandige-losninger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/inndamping-i-vakuum</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/utensilier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/prover-pa-tekniske-egenskaper</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/european-paediatric-formulary</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/oppbevaring-og-merking/mikrobiologisk-kvalitet-av-legemilder</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/generelle-bestemmelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/definisjoner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/oppbevarings--og-transportbetingelser-inkludert-merking</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/oppbevarings--og-transportbetingelser-inkludert-merking/oppbevaringsbetingelser-hos-bruker</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/oppbevarings--og-transportbetingelser-inkludert-merking/oppbevaringsbegreper-fra-tidligere-nls-utgaver</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/legemidler-etter-anbrudd</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/legemidler-etter-anbrudd/legemidler-med-krav-om-sterilitet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/nls/nasjonale-veiledninger/legemidler-etter-anbrudd/legemidler-uten-krav-om-sterilitet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/meld-bivirkninger/bivirkningsregisteret</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/meld-bivirkninger/informasjonsmateriell-bivirkningsmelding</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/arsrapporter-bivirkninger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/temarapporter-om-bivirkninger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/temarapporter-om-bivirkninger/bivirkningsrapporter-for-koronavaksiner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/temarapporter-om-bivirkninger/bivirkningsrapporter-for-koronavaksiner/koronavaksiner-og-betennelse-i-hjertet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/temarapporter-om-bivirkninger/bivirkningsrapporter-for-koronavaksiner/koronavaksiner-og-menstruasjonsforstyrrelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/temarapporter-om-bivirkninger/meldte-bivirkninger-av-sglt2-hemmere</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/temarapporter-om-bivirkninger/meldte-bivirkninger-av-hpv-vaksine</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/bivirkninger-av-ditt-legemiddel</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/whos-bivirkningsoversikt</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/bivirkningsrapporter-og-oversikter/oversikt-over-bivirkningsmeldinger-i-europa</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/legemiddelovervaking/slik-overvakes-bivirkninger-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/legemiddelovervaking/svart-trekant-hva-betyr-det</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/legemiddelovervaking/laboratoriekontroll-av-legemiddel</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-pasienter/regelverk-for-import-omsetning-og-bruk-av-medisinsk-cannabis</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-pasienter/10-medisintips-for-ferien</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/homoopatiske-legemiddel</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/p-piller</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/app-for-legemiddelregning</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/legemiddelgjennomgang</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/nesespray-og-draper-mot-nesetetthet-anbefales-ikke-til-barn-under-2-ar</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/nytt-om-legemidler-nyl</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/bruk-av-desinfeksjonsmidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/plantebaserte-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/interaksjonsdata-fra-dmp/stotteinformasjon-i-interaksjonene</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/interaksjonsdata-fra-dmp/prinsipper-for-sok-i-interaksjonsdatabasen</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/interaksjonsdata-fra-dmp/klassifisering-av-interaksjonene</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/interaksjonsdata-fra-dmp/inklusjonskriterier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/interaksjonsdata-fra-dmp/dokumentasjon-av-interaksjonsdata</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/interaksjonsdata-fra-dmp/forvaltning-og-oppdatering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger/sikkerhetsinformasjon-til-helsepersonell-og-pasient</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger/sikkerhetsinformasjon-til-helsepersonell-og-pasient/kjere-helsepersonell-brev</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger/reseptfrie-legemidler-med-krav-om-veiledning</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger/reseptfrie-legemidler-med-krav-om-veiledning/reseptfri-sildenafil</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger/reseptfrie-legemidler-med-krav-om-veiledning/reseptfri-tadalafil</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger/reseptfrie-legemidler-med-krav-om-veiledning/reseptfri-hoykonsentrert-fluoridtannpasta</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/tiltak-for-a-forebygge-bivirkninger/reseptfrie-legemidler-med-krav-om-veiledning/ventizolve</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/regelverk-for-oppfolging-av-legemiddelsikkerhet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/rutiner-for-innhenting-av-tilleggsopplysninger-for-bivirkningsmeldinger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/rutiner-for-varsling-av-emerging-safety-issues</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/psur-repository-obligatorisk-ved-innsendelse-av-psur</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/standardmerking-av-sikkerhetsinformasjon-til-helsepersonell</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/ofte-stilte-sporsmal-om-legemiddelovervaking</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/inspeksjon-av-mt--innehavers-systemer-for-legemiddelovervaking</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/bivirkninger-og-sikkerhet/sikkerhetsinformasjon-for-legemiddelfirma/inspeksjon-av-mt-innehavers-systemer-for-legemiddelovervaking--veterinar</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-leger-og-tannleger/legemidler-det-ofte-er-sporsmal-om-ved-godkjenningsfritak/behandling-med-cannabis-innenfor-dagens-regelverk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-leger-og-tannleger/bruk-av-markedsforte-melatonin-produkter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-leger-og-tannleger/medisinske-gasser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-apotek/negativlisten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenningsfritak/for-apotek/ekspederingslisten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/oversikt-over-legemiddelmangel---for-pasienter-og-helsepersonell</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/oversikt-over-legemiddelmangel---for-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/nyheter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/informasjon-for-legemiddelfirma</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/informasjon-for-legemiddelfirma/soknad-om-tillatelse-til-salg-av-utenlandske-pakninger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/legemiddelmangel-arsaker-og-tiltak</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/rasjonering-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/forsyningssikkerhet-og-beredskap/malbilde-for-forsyningssikkerhet-og-beredskap</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/forsyningssikkerhet-og-beredskap/aktoroversikt</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/forsyningssikkerhet-og-beredskap/beredskapslagre-for-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/forsyningssikkerhet-og-beredskap/utvalg-for-forsyningssikkerhet-og-beredskap-for-medisinske-produkter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/veiledning-og-regelverk/regelverket-for-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/veiledning-og-regelverk/veiledere-fra-eu-kommisjonenmdcg</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/veiledning-og-regelverk/overgangsordninger-for-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/veiledning-og-regelverk/utstyr-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/veiledning-og-regelverk/webinarer-om-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/kvalifisering-og-klassifisering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/kvalifisering-og-klassifisering/kvalifisering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/kvalifisering-og-klassifisering/klassifisering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/kvalifisering-og-klassifisering/grenseprodukter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms/teknisk-dokumentasjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms/klinisk-evaluering-og-ytelsesevaluering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms/kvalitetsstyringssystem</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms/person-med-ansvar-for-a-overholde-regelverket</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms/standarder-og-fellesspesifikasjoner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms/sprakkrav-og-informasjon-som-skal-folge-utstyret</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/dokumentasjonqms/unik-utstyrsidentifikasjon-udi</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/samsvarsvurdering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/samsvarsvurdering/samsvarsvurdering-som-involverer-meldt-organ</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/samsvarsvurdering/samsvarsvurdering-uten-meldt-organ</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/samsvarsvurdering/samsvarserklering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/samsvarsvurdering/ce-merking</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/samsvarsvurdering/unntak-fra-samsvarsvurdering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/samsvarsvurdering/free-sales-certificate</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/spesielle-typer-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/spesielle-typer-medisinsk-utstyr/produkter-uten-medisinsk-formal</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/spesielle-typer-medisinsk-utstyr/individuelt-tilpasset-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/spesielle-typer-medisinsk-utstyr/systemer-og-prosedyresett-med-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/tilsyn-med-produsenter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/utvikling-og-produksjon/overvaking-etter-at-utstyr-er-plassert-pa-markedet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/programvare-som-medisinsk-utstyr/kvalifisering-og-klassifisering-av-programvare</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/programvare-som-medisinsk-utstyr/krav-for-programvare-som-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/meldeplikt-ved-mangel-pa-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/krav-til-markedsdeltakere</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/krav-til-markedsdeltakere/krav-til-produsenter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/krav-til-markedsdeltakere/krav-til-autoriserte-representanter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/krav-til-markedsdeltakere/krav-til-importorer-og-distributorer</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/krav-til-markedsdeltakere/krav-til-helseinstitusjoner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/krav-til-markedsdeltakere/nar-far-man-produsentansvaret</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/fjernsalg-og-netthandel-med-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/tilsyn-med-importorer-og-distributorer</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/deler-og-komponenter-som-endrer-ytelse-eller-tiltenkt-bruk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/reklame-for-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/reklame-for-medisinsk-utstyr/veiledning-om-markedsforing-av-kosmetiske-inngrep</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/reklame-for-medisinsk-utstyr/veiledning-om-reklame-for-fillere</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/reklame-for-medisinsk-utstyr/sanksjonsmuligheter-ulovlig-reklame</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/omsetning/reklame-for-medisinsk-utstyr/sanksjonsmuligheter-ulovlig-reklame/vedtak-om-brudd-pa-reklameregelverket</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/eudamed/registrering-av-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/introduksjon-til-klinisk-utproving-av-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/soknadspliktige-kliniske-utprovinger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/meldepliktige-kliniske-utprovinger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/andre-kliniske-utprovinger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/sikkerhetsrapportering-i-klinisk-utproving-av-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/vesentlige-endringer-av-en-klinisk-utproving</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/avslutning-eller-midlertidig-stans-av-en-klinisk-utproving</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/klinisk-utproving-av-medisinsk-utstyr/kliniske-utprovinger-startet-opp-for-26-mai-2021</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/introduksjon-til-ytelsesstudier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/soknadspliktige-ytelsesstudier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/meldepliktige-ytelsesstudier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/meldepliktige-ytelsesstudier/Post-market-performance-follow-up-studier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/meldepliktige-ytelsesstudier/studier-av-utstyr-til-behandlingsveiledende-diagnostikk-med-bruk-av-restprover</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/andre-ytelsesstudier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/kombinasjonsstudier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/sikkerhetsrapportering-i-ytelsesstudier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/vesentlige-endringer-av-en-ytelsesstudie</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/ytelsesstudie-av-ivd-utstyr/avslutning-eller-midlertidig-stans-av-en-ytelsesstudie</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/hendelser-og-sikkerhetstiltak/alvorlige-hendelser-med-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/hendelser-og-sikkerhetstiltak/hvordan-rapportere-en-alvorlig-hendelse</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/hendelser-og-sikkerhetstiltak/korrigerende-sikkerhetstiltak</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/hendelser-og-sikkerhetstiltak/hvordan-rapportere-et-korrigerende-sikkerhetstiltak</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/for-helsetjenesten/alvorlige-hendelser-for-helsetjenesten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/for-helsetjenesten/korrigerende-sikkerhetstiltak-i-helsetjenesten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/for-helsetjenesten/handtering-av-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/for-helsetjenesten/reprosessering-av-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/for-helsetjenesten/egentilvirkning-av-medisinsk-utstyr-i-helseinstitusjoner-in-house</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/medisinsk-utstyr/for-helsetjenesten/sentralgassanlegg-for-medisinske-gasser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/offentlig-finansiering-av-legemidler-og-medisinsk-utstyr/hva-inneberer-prioriteringskriteriene-ressursbruk-nytte-og-alvorlighet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/offentlig-finansiering-av-legemidler-og-medisinsk-utstyr/bruk-av-nye-legemidler-i-offentlige-sykehus-for-beslutning-om-finansiering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anmodning-og-forslag/anmodning-og-forslag-for-blaresept-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anmodning-og-forslag/metodevarsler-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anmodning-og-forslag/metodevarsler-for-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anmodning-og-forslag/pipeline-moter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-vaksiner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-vaksiner/innforing-av-vaksiner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-vaksiner/vaksiner-under-vurdering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-vaksiner/anmodning-av-nye-vaksiner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/saksbehandlingsstatus</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/prosjektplaner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon/varsling-og-prosess-for-innsending-av-dokumentasjon-til-metodevurdering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon/retningslinjer-for-dokumentasjonsgrunnlag-for-metodevurdering-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon/veiledning-til-formoter-i-forbindelse-med-metodevurdering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon/mal-for-innsending-av-dokumentasjon-for-metodevurdering-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon/legemidler-der-forskriften-gjor-unntak-fra-krav-til-dokumentasjon-ved-metodevurdering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon/hvordan-sikre-tilgang-til-legemidler-for-serskilt-sma-pasientgrupper-med-svert-alvorlig-tilstand</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/innsending-av-dokumentasjon/enhetskostnadsdatabase</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-medisinsk-utstyr/innsending-av-dokumentasjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-medisinsk-utstyr/prosjektplaner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-medisinsk-utstyr/fullforte-metodevurderinger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/brukerinnspill-nar-vi-vurderer-nytte-og-kostnad-ved-nye-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/fageksperters-rolle</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/internasjonalt-samarbeid</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/internasjonalt-samarbeid/eu-forordning-om-metodevurdering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/internasjonalt-samarbeid/nordisk-samarbeid-om-helseokonomiske-vurderinger</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/pris-pa-legemidler/trinnpris</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/pris-pa-legemidler/pris-pa-legemidler-som-utleveres-av-lege-tannlege-veteriner-og-private-sykehus</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/pris-pa-legemidler/apotekavanse</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/medisinbytte-i-apotek/apotekets-rolle-i-bytteordningen</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/medisinbytte-i-apotek/legens-rolle-i-bytteordningen</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/medisinbytte-i-apotek/virkestoffrekvirering---veiledning-til-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/medisinbytte-i-apotek/horing-om-opptak-pa-byttelisten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/endringer-i-refusjon-av-diabeteslegemidler/-individuell-stonad-for-ozempic-og-rybelsus</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/endringer-i-refusjon-av-diabeteslegemidler/fjerning-av-refusjon-for-utenlandske-pakninger-med-ozempic</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/vaksiner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/vaksiner/samarbeidsavtale</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/vaksiner/spesialistgruppe</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/vaksiner/oversikt-over-anskaffelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/anbud---blaresept</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/anbud---blaresept/kriterier-for-utvelgelse-av-legemidler-til-anbud</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/anbud---blaresept/spesialist--og-brukergrupper</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/offentlig-finansiering/anskaffelser/anbud---blaresept/gjennomforing-av-anbudsonkurranse-om-legemidler-pa-blaresept</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/apotekoversikt</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/e-resept-viktig-informasjon-vedrorende-organisasjonsnummer-og-apningsdato</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/nettapotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/registreringsordning-for-netthandel-med-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/registreringsordning-for-netthandel-med-legemidler/registrerte-nettapotek-og-andre-utsalgssteder-for-salg-av-legemidler-pa-nett</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/melding-om-apoteka-sine-opningstider</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/schengen-attest</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/schengen-attest/skjema-og-veiledning-for-schengen-attest</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/schengen-attest/schengen-veiledning-for-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/schengen-attest/eksempler-pa-legemidler-som-er-omfattet-av-schengen-attestbestemmelsene-i-norge</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/apotektillatelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/apotektillatelser/retningslinjer-for-bruk-av-apotekloven-2-8-og-for-driftsstotte-til-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/tilsyn-med-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/veiledning-for-apotek-om-narkotikaregnskap-oppbevaring-og-meldeplikt-ved-tap-av-narkotika</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekdrift/veiledning-vedrorende-avvik-ved-apotektilvirkning</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekokonomi/apotekstatistikk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekokonomi/fraktrefusjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekokonomi/regnskapsrapportering-for-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/apotekokonomi/soknad-om-driftsstotte-for-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/avgifter/legemiddelleverandoravgift</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/avgifter/lua-avgift</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/avgifter/legemiddeldetaljistavgift</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk/privatimport-ved-forsendelse</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk/legemidler-pa-reise-inn-til-norge</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk/legemidler-pa-reise-ut-av-norge</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/virksomheter-som-kan-importere</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/virksomheter-som-kan-importere/oversikt-over-virksomheter-med-importtillatelse-for-legemidler-til-ikke-medisinsk-bruk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/virksomheter-som-kan-importere/godkjente-legemiddelgrossister</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/virksomheter-som-kan-importere/eos-tilvirkere-og-eos-grossister-som-utover-grossistvirksomhet-i-norge</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/soknad-om-grossisttillatelse</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/tilsyn-med-tilvirkere-og-grossistvirksomhet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/retningslinjer-for-sikring-av-legemidler-under-transport</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/retningslinjer-for-kontrolltelling-av-narkotika-herunder-legemidler-i-reseptgruppe-a-og-b-for-importorer-av-legemidler-til-ikke-medisinsk-bruk-tilvirkere-og-grossister</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/lager-og-oppbevaring</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/lager-og-oppbevaring/veiledning-til-legemiddelgrossister-og-legemiddeltilvirkere-om-innbruddssikring-av-lokaler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/lager-og-oppbevaring/retningslinjer-for-kontroll-med-temperatur-ved-lagring-og-transport-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/lager-og-oppbevaring/andre-serskilte-krav-til-oppbevaring-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/kvalitetssystem-og-kvalitetshandbok</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/krav-til-personale-ffa</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/grossistvirksomhet-med-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/gavesendingar-til-utlandet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/distribusjon-retur-og-destruksjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/distribusjon-retur-og-destruksjon/retningslinjer-for-retur-av-legemidler-fra-apotek-til-salgbart-lager-hos-grossist</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/distribusjon-retur-og-destruksjon/kvalifisering-og-godkjenning-av-leverandorer-og-kunder</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/distribusjon-retur-og-destruksjon/destruksjon-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/krav-og-veiledninger-for-grossistvirksomhet/distribusjon-retur-og-destruksjon/certificate-of-conformance-coc</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/tilleggskrav-til-grossister-i-henhold-til-nasjonalt-regelverk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/tilleggskrav-til-grossister-i-henhold-til-nasjonalt-regelverk/veileder-for-detaljomsetning-av-medisinske-gasser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/tilleggskrav-til-grossister-i-henhold-til-nasjonalt-regelverk/salg-av-medisinske-gasser-til-ikke-medisinsk-bruk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/tilleggskrav-til-grossister-i-henhold-til-nasjonalt-regelverk/retningslinjer-for-direktesalg-av-legemidler-til-sykehus</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/tilleggskrav-til-grossister-i-henhold-til-nasjonalt-regelverk/grossisters-leveringsplikt</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/legemiddelformidlere-brokers</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/import-av-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/import-av-legemidler/fiskal-import</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/import-av-legemidler/importtillatelse-for-legemidler-til-ikke-medisinsk-bruk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/import-av-legemidler/import-av-legemidler-fra-land-utenfor-eos-omradet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/import-av-legemidler/import-av-apotektilvirkede-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/grossistvirksomhet-med-tillatelse-fra-annen-eos-myndighet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/skipsmedisin-og-legemidler-til-redningsmidler-pa-skip</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/import-og-grossistvirksomhet-med-legemidler/tiltak-ved-kvalitetssvikt-pa-legemidler/kjare-helsepersonell-brev-om-kvalitetssvikt</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/narkotika-og-doping/narkotikalisten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/narkotika-og-doping/handtering-av-narkotika-i-industrien</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/narkotika-og-doping/doping</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/narkotika-og-doping/narkotikatillatelser-til-ikke-medisinsk-bruk-narkotikaprekursorer-og-transitt</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/eksterne-foredragsholdere</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/helse-og-sykdomsinformasjon-i-reklamesammenheng-</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/veiledning-for-teknisk-administrering-av-legemidler-med-hensyn-til-reklamebestemmelsene</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/reklame-for-legemidler-pa-internett</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/soknad-om-vaksinasjonskampanje-til-allmennheten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/minimumsinformasjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/bruk-av-abstrakt-til-kongresser-som-referanse-i-legemiddelreklame</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/retningslinjer-for-distribusjon-av-gratis-legemiddelprover</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/innsendelse-av-all-reklame-for-legemidler-</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/generelt-om-reklameregelverket/moter-med-reklame-for-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/tilsyn-og-sanksjonsmuligheter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/tilsyn-og-sanksjonsmuligheter/rapporter-fra-muntlige-reklametilsyn</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/tilsyn-og-sanksjonsmuligheter/sanksjonsmuligheter-ulovlig-reklame</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/tilsyn-og-sanksjonsmuligheter/tips-oss-om-ulovlig-legemiddelreklame</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/tilsyn-og-sanksjonsmuligheter/vedtak-om-brudd-pa-reklameregelverket</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/tilsyn-og-sanksjonsmuligheter/nettsider-med-ulovlig-informasjon-om-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/informasjon-for-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/informasjon-for-apotek/nettapotek-og-informasjon-om-reseptpliktige-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/informasjon-for-apotek/veileder-for-apotek-som-tilbyr-vaksinasjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/informasjon-for-klinikker</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/reklame-for-legemidler/informasjon-for-klinikker/veileder-for-estetiske-klinikker</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/salg-utenom-apotek/veiledning-til-utsalgssteder-som-skal-selge-legemidler-utenom-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/salg-utenom-apotek/salg-av-reseptfrie-legemidler-til-akvariefisk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/salg-utenom-apotek/minimumsutvalg-salg-av-legemidler-utenom-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/salg-utenom-apotek/liste-over-legemidler-som-kan-omsettes-utenfor-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/sikkerhetsanordninger-for-legemidler/melding-om-mulig-forfalsket-legemiddel</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/apoteka-sitt-hove-til-produksjon-av-legemiddel-til-kliniske-studiar</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/gmp-sertifikat-ved-tilverking-av-verkestoff</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/maskinell-dosepakking-av-legemiddel</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/retningslinjer-for-bruk-av-bulkpakningar-ved-maskinell-dosedispensering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/soknad-om-tilvirkertillatelse</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/tilvirkertillatelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/tilvirkertillatelser/godkjende-tilverkarar-tilvirkere</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/tilvirkning-av-legemidler/tilvirkning-av-infusjonspreparater-til-bruk-i-iv-terapi</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/utlevering-og-salg-i-apotek/veiledning-om-dokumentasjonsplikt-i-apotek</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/utlevering-og-salg-i-apotek/veiledning-for-apotekenes-netthandel-med-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/utlevering-og-salg-i-apotek/veileder-til-forskrift-om-rekvirering-og-utlevering-av-legemidler-mm</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/utlevering-og-salg-i-apotek/utleveringsbestemmelser-for-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/utlevering-og-salg-i-apotek/utleveringsbestemmelser-for-legemidler/vedtak-om-utleveringsbestemmelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/tilvirkning-import-og-salg/utlevering-og-salg-i-apotek/utlevering-av-reseptpliktige-legemiddel-som-i-avgrensa-mengde-er-unnateke-reseptplikt-fra-apotek-og-medisinutsal</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/spesielt-godkjenningsfritak-for-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/spesielt-godkjenningsfritak-for-legemidler-til-dyr/webinar-om-godkjenningsfritak-for-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/spesielt-godkjenningsfritak-for-legemidler-til-dyr/legemidler-det-har-blitt-sokt-om-godkjenningsfritak-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/spesielt-godkjenningsfritak-for-legemidler-til-dyr/informasjon-til-apotek-om-elektronisk-losning-for-godkjenningsfritak-for-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/veteriner-bruk-av-humanpreparater-med-utleveringsbestemmelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/autogene-vaksiner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/premiks-til-utlevering-til-dyreeier</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/Godkjenningsfritak-og-legemidler-som-veteriner-fiskehelsebiolog-ma-soke-om/rekvirering-av-rensubstans-inkludert-legemiddelfr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/klinisk-utproving-av-legemidler-til-dyr/retningslinjer-for-klinisk-utproving-av-vaksiner-til-fisk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/mangel-pa-veterinere-legemidler/rad-til-veterinarer-og-dyreeiere-ved-legemiddelmangel</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/mangel-pa-veterinere-legemidler/ofte-stilte-sporsmal-om-tilgjengelighet-av-legemidler-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/mangel-pa-veterinere-legemidler/legemiddelmangel-pa-veterinere-legemidler-arsaker-og-tiltak</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/fisk/godkjente-legemidler-til-fisk</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-matproduserende-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-matproduserende-dyr/forord</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-matproduserende-dyr/generelle-forhold</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-matproduserende-dyr/terapianbefalinger-for-svin</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-matproduserende-dyr/terapianbefalinger-for-storfe</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-matproduserende-dyr/terapianbefalinger-for-sau</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-matproduserende-dyr/terapianbefalinger-for-geit</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/reseptstatus-for-humanlegemidler-brukt-til-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/forord</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/generelle-forhold</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/sarbehandling-og-sarinfeksjoner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/luftveisorganene</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/fordoyelsessystemet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/follinfeksjoner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/urinveisorganer</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/profylaktisk-perioperativ-bruk-av-antibiotika</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/oyne</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/kjonnsorganer</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bruk-av-antibakterielle-midler-til-hest/flattbarne-infeksjoner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/forsvarlig-bruk-av-antibiotika-hos-dyr</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/terapianbefaling-behandling-av-bier-for-bekjempelse-av-varroa-destructor</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/medisiner-til-hund-og-katt-mot-innvollsorm-krever-resept</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/legemidler-og-mattrygghet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/bier-og-legemidler</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/blod-og-blodkomponenter-blodtransfusjon-irap-og-prp-i-veterinermedisinen</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/veterinermedisin/terapianbefalinger-og-forskrivning-av-legemidler-til-dyr/forebygging-av-flattangrep-og-insektplager-hos-hest-hund-og-katt</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/blodgivning-og-transfusjonsmedisin/godkjente-blodbanker</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/blodgivning-og-transfusjonsmedisin/tilsyn-med-blodbankar</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/blodgivning-og-transfusjonsmedisin/meld-uonsket-hendelse-blodgivning-og-blodtransfusjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/blodgivning-og-transfusjonsmedisin/overvaking-av-blod---arsrapporter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/godkjenning-av-virksomheter-for-handtering-av-celler-og-vev</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/virksomheter-godkjent-for-handtering-av-humane-celler-og-vev</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/1.-innledende-bestemmelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/2.-ledelse-organisering-og-styring-av-virksomheten</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/3.-krav-til-virksomhetenes-lokaler-og-utstyr-mv.-ved-prosessering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/4.-donasjon-og-laboratorieundersokelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/5.-lovlig-uttak-informasjon-opplysninger-og-prosedyrer-i-forbindelse-med-donasjon</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/6.-prosessering-oppbevaring-distribusjon-og-mottak</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/7.-emballering-og-merking</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/8.-sporbarhet-tilbakekall-kvalitet-og-sikkerhet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/9.-virksomhetens-donasjonsregister</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/10.-sentralisert-meldeordning</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/11.-generelle-bestemmelser</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/handtering-av-humane-celler-og-vev/12.-om-veilederen</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/meld-uonsket-hendelse-celler-og-vev</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/celler-og-vev/informasjon-til-celle--og-vevsvirksomhetene-om-utbrudd-og-smittesituasjoner</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/ny-soho-forordning-fra-2027/registrering-av-soho-virksomheter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/ny-soho-forordning-fra-2027/informasjon-fra-soho-koordineringsradet</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/ny-soho-forordning-fra-2027/kurs-og-opplaring</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/ny-soho-forordning-fra-2027/kartlegging-av-soho-virksomheter</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/blod-celler-og-vev/forvaltning-av-regelverket-for-blod-celler-og-vev-fra-1.-januar-2024</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/presse</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/organisasjon/varsling-om-kritikkverdige-forhold</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/organisasjon/personvernerklering</loc><changefreq>daily</changefreq><priority>0.25</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/kosttilskudd-til-fest-og-fhir-tjenesten</loc><changefreq>daily</changefreq><priority>0.24</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/atc-kodeverk-og-viktigheten-av-femte-niva-for-preparater</loc><changefreq>daily</changefreq><priority>0.23</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/rms-og-norske-kodeverk</loc><changefreq>daily</changefreq><priority>0.23</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/substanser--er-fellesbetegnelsen-for-virkestoff-og-hjelpestoff</loc><changefreq>daily</changefreq><priority>0.22</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere</loc><changefreq>daily</changefreq><priority>0.22</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/databaser-og-digitale-systemet</loc><changefreq>daily</changefreq><priority>0.21</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/batchspesifikke-unntak/soknad-om-batchspesifikke-unntak-relatert-til-kvalitets-dokumentasjon</loc><changefreq>daily</changefreq><priority>0.21</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/batchspesifikke-unntak</loc><changefreq>daily</changefreq><priority>0.21</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/sunset-clause</loc><changefreq>daily</changefreq><priority>0.20</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/avregistrering-midlertidig-utgatt-og-reaktivering</loc><changefreq>daily</changefreq><priority>0.20</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/registreringsgebyr-markedsforingstillatelse-for-legemidler</loc><changefreq>daily</changefreq><priority>0.19</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt</loc><changefreq>daily</changefreq><priority>0.18</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/veiledning-for-navn-pa-legemidler</loc><changefreq>daily</changefreq><priority>0.18</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/implementeringsfrist-for-endringer-som-ikke-berorer-norsk-produktinformasjon</loc><changefreq>daily</changefreq><priority>0.17</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/respons-fra-DMP-for-endringssoknader</loc><changefreq>daily</changefreq><priority>0.17</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/grunnkrav-til-endringssoknader-i-nasjonal-prosedyre</loc><changefreq>daily</changefreq><priority>0.16</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/arbeidsdelingsprosedyre-worksharing-med-nasjonalt-godkjente-legemidler</loc><changefreq>daily</changefreq><priority>0.16</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/artikkel-613-notifikasjoner-og-vra-gi15z-np</loc><changefreq>daily</changefreq><priority>0.15</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.15</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.15</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/overforing-av-mtendret-navn-og-adresse-for-mt-innehaver</loc><changefreq>daily</changefreq><priority>0.15</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/fornyelse-av-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.14</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/nasjonale-mt-soknader-til-dyr-som-er-trukket</loc><changefreq>daily</changefreq><priority>0.13</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/liste-over-nye-markedsforingstillatelser</loc><changefreq>daily</changefreq><priority>0.13</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/pagaende-soknader-om-markedsforingstillatelser</loc><changefreq>daily</changefreq><priority>0.12</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/referansepreparat</loc><changefreq>daily</changefreq><priority>0.12</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/utlysning-av-onskede-preparater-for-a-unnga-legemiddelmangel</loc><changefreq>daily</changefreq><priority>0.12</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/innsending-av-soknader-om-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.11</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/inspeksjoner-av-kliniske-studier</loc><changefreq>daily</changefreq><priority>0.11</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/oversikt-over-antallet-sokte-studier-om-klinisk-utproving</loc><changefreq>daily</changefreq><priority>0.11</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/soknad-om-markedsforingstillatelse-i-sentral-prosedyre</loc><changefreq>daily</changefreq><priority>0.11</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/desentraliserte-kliniske-utprovinger</loc><changefreq>daily</changefreq><priority>0.10</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/desentralisert-prosedyre</loc><changefreq>daily</changefreq><priority>0.10</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-compassionate-use-program</loc><changefreq>daily</changefreq><priority>0.10</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/gjensidig-anerkjennelsesprosedyre-mrp</loc><changefreq>daily</changefreq><priority>0.10</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving-av-gmo-i-legemidler-til-mennesker</loc><changefreq>daily</changefreq><priority>0.09</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/nasjonal-prosedyre-ved-soknad-om-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.09</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/fast-eu-en-pilot-for-raskere-saksbehandling-av-multinasjonale-kliniske-studier</loc><changefreq>daily</changefreq><priority>0.09</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.09</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/rapportering-mens-studien-pagar</loc><changefreq>daily</changefreq><priority>0.08</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/rapportering-nar-studien-er-avsluttet</loc><changefreq>daily</changefreq><priority>0.08</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/avanserte-terapier-sykehusunntak</loc><changefreq>daily</changefreq><priority>0.08</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/gebyrer-for-soknad-om-klinisk-utproving-av-legemidler</loc><changefreq>daily</changefreq><priority>0.07</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/trinnvis-innsendelse-av-soknad-om-klinisk-utproving-article-11-workaround</loc><changefreq>daily</changefreq><priority>0.07</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/lavintervensjonsstudier</loc><changefreq>daily</changefreq><priority>0.06</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/soknad-om-vesentlig-endring</loc><changefreq>daily</changefreq><priority>0.06</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving</loc><changefreq>daily</changefreq><priority>0.06</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving</loc><changefreq>daily</changefreq><priority>0.06</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/soknadsdokumentasjon</loc><changefreq>daily</changefreq><priority>0.06</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/</loc><changefreq>daily</changefreq><priority>0.06</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/</loc><changefreq>daily</changefreq><priority>0.06</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/</loc><changefreq>daily</changefreq><priority>0.05</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/clinical-trials-information-system-ctis</loc><changefreq>daily</changefreq><priority>0.05</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/utvikling-av-legemidler</loc><changefreq>daily</changefreq><priority>0.04</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/</loc><changefreq>daily</changefreq><priority>0.04</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/regelverk-og-veiledninger-for-klinisk-utproving/hva-er-eus-biotech-act</loc><changefreq>daily</changefreq><priority>0.04</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/klinisk-utproving/regelverk-og-veiledninger-for-klinisk-utproving</loc><changefreq>daily</changefreq><priority>0.04</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/</loc><changefreq>daily</changefreq><priority>0.04</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/utvikling-av-legemidler/generisk-legemiddel-og-parallellimportert-legemiddel</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>https://www.dmp.no:443/godkjenning/utvikling-av-legemidler/godkjent-eller-ikke-godkjent-hvilke-statuser-kan-et-legemiddel-ha</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/</loc><changefreq>daily</changefreq><priority>0.03</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:klut@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>https://www.dmp.no:443/</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/veiledning-og-rad</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/Plantebaserte-legemidler/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/</loc><changefreq>daily</changefreq><priority>0.02</priority></url>
<url><loc>http://www.legemiddelverket.no/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/mailto:klut@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/soknad-om-klinisk-utproving/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/homoopatiske-legemidler/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>https://www.dmp.no:443/en</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/sporreundersokelse-om-nytt-saksbehandlingssystem-for-godkjenning-og-oppfolging-av-legemidler</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/horinger</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/utvikling-av-legemidler/</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/mailto:kodeverk@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/anbefalinger-om-oppdatering-av-produktinformasjon/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler/</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/nyheter/mangel-pa-hormonplaster</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/wegovy-i-tablettform-anbefales-godkjent-i-europa</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/nyheter/Diabeteslegemidler-avregistreres</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/oppdatert-veiledning-for-reseptfri-sildenafil</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/horing-om-endringer-i-forskrift-for-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/regulatorisk-informasjonsmote-15.-desember-2026</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/forsyningssikkerhet/legemiddelmangel/nyheter/rasjonering-av-cytotec-tabletter</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/horing---forslag-til-endringer-i-grossistforskriften--5-og-5a</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/arrangement</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/organisasjon</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/organisasjon/strategi</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/organisasjon/styringsdokument</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/distribusjon-av-legemiddeldata</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/announcement-of-needed-products-in-norway</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/digital-package-leaflet</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/classification-of-medicinal-products</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/guidance-and-regulations</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/reporting-of-serious-incidents-involving-medical-devices</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/pricing-of-medicines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/import-and-wholesaling-of-medicines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/content-a-z</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/mailto:klut@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/legislation-and-guidelines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/legislation-and-guidelines/eu-biotech-act</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/clinical-trials-information-system-ctis</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/application-for-clinical-trials</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/application-for-clinical-trials/documentation-requirements-for-clinical-trial-applications</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/application-for-clinical-trials/substantial-modification</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/application-for-clinical-trials/low-intervention-clinical-trials</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/application-for-clinical-trials/fees-for-assessment-of-clinical-trials-and-assessment-of-safety-information</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/application-for-clinical-trials/staged-submission-of-clinical-trial-applications-article-11-workaround</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/reporting-requirements-for-ongoing-clinical-trials-after-approval</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/reporting-when-a-clinical-trial-is-completed</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/fast-eu</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/clinical-trial-application-of-gmo-medicinal-products-for-humans</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/compassionate-use-program</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/decentralised-clinical-trials</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/clinical-trials/overview-of-application-figures</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/nasjonal-prosedyre-ved-soknad-om-markedsforingstillatelse</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/gjensidig-anerkjennelsesprosedyre-mrp</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/decentralised-procedure</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/sentral-prosedyre-cp</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/submission-of-applications</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/list-of-pending-marketing-authorisation-applications</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/list-of-newly-adopted-marketing-authorisations-in-norway</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/renewal-of-ma</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/variations-regarding-marketing-authorisation</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/variations-regarding-marketing-authorisation/transfer-of-machange-in-name-and-address-of-the-mah</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/variations-regarding-marketing-authorisation/article-613-notifications-and-vra-g.i.15z-np</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/variations-regarding-marketing-authorisation/worksharing-procedure</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/variations-regarding-marketing-authorisation/implementation-date-for-variations-that-do-not-affect-norwegian-product-information</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/guideline-for-the-naming-of-medicinal-products</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/regulatory-fees</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/withdrawal-temporary-withdrawal-and-reactivation</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/sunset-clause</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/Batch-specific-exemptions</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/Batch-specific-exemptions/Application-for-batch-specific-exemptions-related-to-quality-documentation</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/databases-and-digital-systems</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/terms-in-medicinal-product-basic-data</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/terms-in-medicinal-product-basic-data/substances-is-the-common-term-for-active-ingredients-and-excipients</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/terms-in-medicinal-product-basic-data/rms-and-norwegian-lists</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/terms-in-medicinal-product-basic-data/atc-index-and-the-importance-of-fifth-level-for-medicinal-products-viktigheten-av-femte-niva-for-preparater</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/relevant-information-regarding-approval-and-maintenance-of-the-MA/terms-in-medicinal-product-basic-data/dietary-supplement-in-fest-and-fhir-service</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/summary-of-product-characteristics-smpc-and-package-leaflet-pil</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/templates-guidelines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/packaging</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/implementation-date-and-batch-specific-exemptions</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/implementation-date-and-batch-specific-exemptions/application-for-batch-specific-exemptions-related-to-product-information</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/recommended-updates</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/recommended-updates/recommendations-after-referral-adopted-by-the-european-commission</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/warning-triangle</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/Product-information---templates-and-guidance/readability-testing-and-bridging</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/medicinal-products-to-be-distributed-without-medical-prescription</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/medicinal-products-to-be-distributed-without-medical-prescription/otc-substance-reports</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/medicinal-products-to-be-distributed-without-medical-prescription/harmonization-of-packaging-leaflet-and-labelling-for-otc-medicinal-products-with-an-otc-substance-report</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/medicinal-products-to-be-distributed-without-medical-prescription/application-for-otc-legal-status-and-change-of-otc-legal-status</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/homeopathic-medicinal-products</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/homeopathic-medicinal-products/homeopathic-medicinal-products-for-human-and-veterinary-use--registration-provisions-in-norway</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/homeopathic-medicinal-products/homeopathic-medicinal-products-for-human-use--simplified-registration-application</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/homeopathic-medicinal-products/homeopathic-veterinary-medicinal-products--simplified-registration-application</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/homeopathic-medicinal-products/registration-of-homeopathic-medicinal-products-for-human-and-veterinary-use--variations-renewals-withdrawals-and-sunset-clause</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/parallel-import</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/parallel-import/application-for-ma-for-parallel-importet-medicinal-products</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/parallel-import/post-marketing-obligations-for-parallel-imported-medicinal-product</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/other-information</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/other-information/whom-to-contact-regarding-regulatory-questions</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/other-information/who-certificates</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/other-information/ocabr-of-human-blood-products-and-vaccines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/disinfectans---approval-manufacturing-and-import</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/The-Norwegian-Adverse-Drug-Reaction-Registry-and-reporting-of-adverse-reactions</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/pharmacovigilance</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/general-information-about-special-permit-named-patient</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-physicians-and-dentists</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-pharmacies</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/information-for-companies-wishing-to-market-medicines-imported-via-special-permit-named-patient</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/security-of-supply</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/security-of-supply/medicine-shortages</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/security-of-supply/NOMAs-role-in-supply-chain-security-and-preparedness</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/eudamed</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/eudamed/actor-registration</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/for-healthcare-facilities</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/horizon-scans-and-assessment-requests</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/medicine-substitution-in-pharmacies</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/fees</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/importing-medicines-for-personal-use</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/manufacturing-of-medicines</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/dispensing-and-sale-of-medicines-in-pharmacies</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/veterinary-medicine</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/veterinary-medicine/reporting-of-adverse-events-for-veterinary-medicinal-products</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/veterinary-medicine/fish-medicine</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/veterinary-medicine/import-and-sale-of-medicines-for-animals</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/blood-cells-and-tissue</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/news</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/forms</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us/contact-us</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us/vacancies</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us/press-service</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/mailto:mt@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/utvikling-av-legemidler/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/utvikling-av-legemidler/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/utvikling-av-legemidler/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/utvikling-av-legemidler/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/regelverk-og-veiledninger-for-klinisk-utproving/</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:gmo@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/bbcb73c52db243de841a2ebbfdbdf549/applicants-template-for-request-to-member-states-to-act-as-rms-in-mrp-srp-or-dcp.docx</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/batchspesifikke-unntak/</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/skjema/godkjenning-av-legemidler/batchspesifikt-unntak-soknadskjema.docx</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/batchspesifikke-unntak/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/distribusjon-av-legemiddeldata/spor</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-preparatomtale-og-pakningsvedlegg/</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/maler-og-veiledninger-for-produktinformasjon/merkingsveiledningen-2.4-12_2022-av-april-24.pdf</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/parallellimporterte-legemidler/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.01</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/disinfectans---approval-manufacturing-and-import/guidance-on-approval-of-disinfectant-for-technical-use-in-health-and-nursing</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/classification-of-medicinal-products/product-specific-guidelines-on-classification</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/approval-of-medicines/classification-of-medicinal-products/product-specific-guidelines-on-classification/products-for-injection-for-fat-removal-are-medicines--not-cosmetics</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/The-Norwegian-Adverse-Drug-Reaction-Registry-and-reporting-of-adverse-reactions/ss</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/The-Norwegian-Adverse-Drug-Reaction-Registry-and-reporting-of-adverse-reactions/how-do-i-report-suspected-adverse-reactions-after-taking-medicines-or-vaccines</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/pharmacovigilance/laboratory-control-of-medicines</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/pharmacovigilance-legislation</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/educational-material---guidance-for-submission-and-distribution</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/guidance-for-submission-of-norwegian-translations-of-direct-healthcare-professional-communication-dhpc</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/procedure-for-follow-up-information-requests-for-adverse-reaction-reports</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/procedure-for-notifying-emerging-safety-issues</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/standardized-labeling-of-safety-information-for-healthcare-professionals</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/frequently-asked-questions-faq--electronic-transmission-of-individual-case-safety-reports-icsrs</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/inspeksjon-av-mt--innehavers-systemer-for-legemiddelovervaking</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/adverse-drug-reactions-and-drug-safety/safety-information-for-the-industry/inspeksjon-av-mt-innehavers-systemer-for-legemiddelovervaking--veterinar</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-physicians-and-dentists/routine-for-special-permit-named-patient-in-hospitals</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-physicians-and-dentists/medicinal-products-frequently-inquired-about-for-special-permit-named-patient</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-physicians-and-dentists/medicinal-products-frequently-inquired-about-for-special-permit-named-patient/procedure-for-treatment-with-cannabis-within-current-regulations</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-physicians-and-dentists/use-og-marketed-melatonin-products</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-physicians-and-dentists/medical-gases</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-pharmacies/which-medicines-can-be-notified--and-which-must-be-assessed-by-noma-before-dispensing</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-pharmacies/negative-list</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/special-permit-named-patient/for-pharmacies/dispensing-list</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/security-of-supply/medicine-shortages/information-for-marketing-authorisation-holders</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/security-of-supply/medicine-shortages/information-for-marketing-authorisation-holders/application-for-license-to-sell-foreign-packages</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/security-of-supply/medicine-shortages/information-for-marketing-authorisation-holders/notification-of-shortages</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/guidance-and-regulations/the-legislation-for-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/guidance-and-regulations/guidance-from-the-eu-commissionmdcg</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/guidance-and-regulations/transitional-provisions-for-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/guidance-and-regulations/devices-for-animals</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/qualification-and-classification</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/qualification-and-classification/qualification</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/qualification-and-classification/classification-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/qualification-and-classification/borderline-products</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/documentation-and-quality-management-system</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/documentation-and-quality-management-system/technical-file</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/documentation-and-quality-management-system/quality-management-system-and-risk-management</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/documentation-and-quality-management-system/person-responsible-for-regulatory-compliance</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/documentation-and-quality-management-system/standards-and-common-specifications</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/documentation-and-quality-management-system/language-requirements-and-information-following-the-medical-device</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/documentation-and-quality-management-system/unique-device--identification-udi-system</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/conformity-assessment</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/conformity-assessment/conformity-assessment-involving-notified-body</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/conformity-assessment/declaration-of-conformity</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/conformity-assessment/ce-marking-of-conformity</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/conformity-assessment/derogation-from-the-conformity-assessment-procedure</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/conformity-assessment/free-sales-certificate</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/devices-for-special-purposes</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/devices-for-special-purposes/systems-and-procedure-packs-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/devices-for-special-purposes/custom-made-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/development-and-manufacturing/monitoring-after-device-is-placed-on-the-market</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/notification-requirement-for-forecasted-shortages-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/distance-salesonline-salese-commerce</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/market-surveillance-and-auditing-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/the-different-roles-of-economic-operators</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/the-different-roles-of-economic-operators/general-obligations-for-manufacturers-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/the-different-roles-of-economic-operators/general-obligations-for-authorised-representatives-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/the-different-roles-of-economic-operators/general-obligations-for-importers-and-distributors-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/the-different-roles-of-economic-operators/general-obligations-for-health-institutions-when-using-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/the-different-roles-of-economic-operators/cases-in-which-obligations-of-manufacturers-apply-to-importers-distributors-or-other-persons</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/parts-and-components-that-change-performance-or-intended-purpose</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/sale-import-and-distribution/advertising-for-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/eudamed/registration-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/introduction-to-clinical-investigation-of-a-medical-device</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/clinical-investigations-which-require-an-application-to-noma</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/clinical-investigations-which-require-a-notification-to-noma</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/clinical-investigations-which-do-not-require-an-application-or-a-notification-to-noma</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/safety-reporting-in-clinical-investigations-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/substantial-modifications-to-clinical-investigations</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/end-or-temporary-halt-of-a-clinical-investigation</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/clinical-investigation-of-medical-devices/transitioning-from-the-old-eu-directives-to-the-new-regulation-eu-2017745-mdr</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/introduction-to-performance-studies-of-ivd-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/performance-studies-that-must-be-applied-for-to-noma</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/performance-studies-which-require-a-notification-to-noma</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/performance-studies-which-require-a-notification-to-noma/post-market-performance-follow-up-studies</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/performance-studies-which-require-a-notification-to-noma/studies-involving-companion-diagnostics-cdx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/performance-studies-which-shall-not-be-applied-for-or-notified-to-noma</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/combined-studies</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/safety-reporting-in-performance-studies</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/substantial-modifications-to-a-performance-study</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/performance-studies-of-in-vitro-diagnostic-medical-devices/end-or-temporary-halt-of-a-performance-study</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/reporting-of-serious-incidents-involving-medical-devices/alvorlige-hendelser-med-medisinsk-utstyr</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/reporting-of-serious-incidents-involving-medical-devices/how-to-report-a-serious-incident</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/reporting-of-serious-incidents-involving-medical-devices/korrigerende-sikkerhetstiltak</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/reporting-of-serious-incidents-involving-medical-devices/how-to-report-a-field-safety-corrective-action</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/for-healthcare-facilities/melde-fra-om-alvorlige-hendelser-i-helsetjenesten</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/for-healthcare-facilities/korrigerende-sikkerhetstiltak-pa-utstyr-i-helsetjenesten</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/medical-devices/for-healthcare-facilities/medical-gas-pipeline-systems</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/horizon-scans-and-assessment-requests/horizon-scanning-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/horizon-scans-and-assessment-requests/horizon-scanning-or-request-for-assessment</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/horizon-scans-and-assessment-requests/pipeline-meetings</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/single-technology-assessments---status-and-reports</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals/notification-and-process-for-submitting-documentation</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals/guidelines-for-the-submission-of-documentation-for-single-technology-assessment-sta-of-pharmaceuticals</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals/Consultatory-meetings</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals/template-for-submission-of-documentation-for-the-single-technology-assessment-of-pharmaceuticals</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals/pharmaceuticals-for-which-the-regulation-on-medicinal-products-grants-exceptions-from-the-documentation-requirements-for-single-technology-assessments-stas</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals/access-to-pharmaceuticals-for-very-small-patient-groups-with-extremely-severe-conditions</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/medicines/submission-of-documentation-for-single-technology-assessment-of-pharmaceuticals/unit-cost-database</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/submission-of-documentationtation-for-single-technology-assessment-of-medical-devices</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/submission-of-documentationtation-for-single-technology-assessment-of-medical-devices/innsending-av-dokumentasjon</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/submission-of-documentationtation-for-single-technology-assessment-of-medical-devices/planned-assessments</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/submission-of-documentationtation-for-single-technology-assessment-of-medical-devices/fullforte-metodevurderinger</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/international-cooperation</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/international-cooperation/eu-regulation-on-health-technology-assessment-htar</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/health-technology-assessments/international-cooperation/finose</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/pricing-of-medicines/maximum-price</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/medicine-substitution-in-pharmacies/what-are-substitutable-medicines</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/medicine-substitution-in-pharmacies/the-substitution-list</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/medicine-substitution-in-pharmacies/the-role-of-pharmacies-in-the-substitution-scheme</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/medicine-substitution-in-pharmacies/the-physicians-role-in-the-substitution-scheme</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/public-funding-and-pricing/medicine-substitution-in-pharmacies/consultations-on-inclusion-in-the-substitution-list</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/fees/supplier-tax</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/importing-medicines-for-personal-use/importing-medicines-for-personal-use-in-the-form-of-consignments</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/importing-medicines-for-personal-use/bringing-medicines-into-norway-by-travel</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/importing-medicines-for-personal-use/taking-medicines-out-of-norway</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/import-and-wholesaling-of-medicines/companies-authorised-to-import-medicines-to-norway</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/import-and-wholesaling-of-medicines/companies-authorised-to-import-medicines-to-norway/companies-performing-wholesaler-activities-based-on-authorisation-issued--within-the-eueea</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/import-and-wholesaling-of-medicines/import-of-medicines</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/import-and-wholesaling-of-medicines/import-of-medicines/import-of-medicinal-products-for-clinical-studies-in-norway</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/import-and-wholesaling-of-medicines/wholesaling-in-norway-based-on-a-mia-or-a-wda-issued-within-the-eueea</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/import-and-wholesaling-of-medicines/handling-quality-defects-of-medicines</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/manufacturing-of-medicines/guideline-on-use-of-bulk-packages-with-automated-dose-dispensing</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/manufacturing-import-and-retailing-of-medicines/dispensing-and-sale-of-medicines-in-pharmacies/dispensing-regulations</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/veterinary-medicine/fish-medicine/approved-medicines-for-use-in-fish</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/news/survey-on-the-new-case-management-system-for-the-approval-and-monitoring-of-medicinal-products</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/news/joint-european-health-technology-assessments-underway-at-noma</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/news/new-safety-module-in-clinical-trials-information-system-ctis</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/news/pilot-on-common-nordic-packages-in-english-language-is-extended</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/news/call-for-tender-assessment-of-the-health-opportunity-cost-in-norway</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/news/new-notification-form-for-medicine-shortages</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us/organisation-and-tasks</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us/guidance-and-advice-for-companies-and-academia</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us/the-norwegian-health-care-system-and-pharmaceutical-system</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/mailto:post@noma.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/en/about-us/organisation-and-tasks/privacy-policy</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/organisasjon/fagomrader</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/ny-sikkerhetsmodul-for-aarsrapporter-i-ctis</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/ny-nasjonal-handlingsplan-for-kliniske-studier</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/eu-kommisjonen-lanserer-forste-del-av-nytt-bioteknologiregelverk</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/pilot-for-raskere-saksbehandling-av-soknader-om-klinisk-utproving</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/mailto:ask-us@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:ask-us@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/regelverk-og-veiledninger-for-klinisk-utproving/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/regelverk-og-veiledninger-for-klinisk-utproving/mailto:klut@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/regelverk-og-veiledninger-for-klinisk-utproving/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/regelverk-og-veiledninger-for-klinisk-utproving/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:GMO@DMP.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:RA@afyxtx.com</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:a.dahlberg@medac.se</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klinisk-utproving/mailto:tilsyn@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/8fc05eb061854974b1eeabf5c16c6b55/klut---tall-for-2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/fellesnordiske-engelskspraklige-pakninger-forlenges</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/klassifisering/avansert-terapi?WebId=ee9d310e-0b44-4106-a4ea-80c3d1da1659&amp;TermSetId=a67f242d-2a99-4fce-9085-05f119ee0213&amp;TermId=f1624b3b-2e03-433f-91f9-51bd5d8d6e16</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/avanserte-terapier/retningslinjer_for_soknad_om_sykehusunntak_juni_2013.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/avanserte-terapier/flytskjema-for-hospital-exemption.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/mailto:atmp_postboks@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/464e9e1b6d1d4788ba6bbcc5db4f9d6b/planned-submission-of-a-national-procedure---2025.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/bbcb73c52db243de841a2ebbfdbdf549/appendix-1-to-request-for-mrp-rup-for-medicinal-products-for-human-use.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/6b5c7b12f3fa46e38098be9ab115ffa8/cmdh_036_2009_rev5_2025_09_clean_-_dcp_rms_request.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/6b5c7b12f3fa46e38098be9ab115ffa8/applicants-template-for-request-to-member-states-to-act-as-rms-in-mrp-srp-or-dcp.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/mailto:mangelforebygging@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/soknad-om-mt/dokumentbeskyttelse-og-erp_-dra-6.juni-2011.ppt</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/soknad-om-mt/mt_soknader.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-august-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-juli-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-juni-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-mai-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-april-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-mars-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-februar-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2026/nye-markedsforingstillatelser-januar-2026.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-desember-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-november-2025-1.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-oktober-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-september-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-august-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-juli-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-juni-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-mai-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-april-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-mars-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-februar-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2025/nye-markedsforingstillatelser-januar-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-desember-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-november-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-oktober-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-september-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-august-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-juli-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-juni-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-mai-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-april-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-mars-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-februar-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2024/nye-markedsforingstillatelser-januar-2024.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-desember-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-november-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-oktober-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-september-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-august-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-juli-20231.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-juni-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-mai-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-april-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-mars-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-februar-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2023/nye-markedsforingstillatelser-januar-2023.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-desember-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/markedsforingstillatelser-november-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-oktober-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/markedsforingstillatelser-september-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-august-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-juli-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-juni-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-mai-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-april-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-mars-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-februar-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2022/nye-markedsforingstillatelser-januar-2022.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-desember-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-november-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-oktober-2021a.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-september-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-august-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-juli-2021-002.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-juni-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-mai-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-april-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-mars-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-februar-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2021/nye-markedsforingstillatelser-januar-2021.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-desember-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-november-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-oktober-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-september-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-august-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-juli-2020b.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/markedsforingstillatelser-juni-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-mai-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-april-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-mars-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-februar-2020.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2020/nye-markedsforingstillatelser-januar-2020_a.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-desember-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-november-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-oktober-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-september-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-august-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-juli-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/oppdatering-av-produktinformasjon/nye-markedsforingstillatelser-juni-2019b.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/markedsforingstillatelser-mai-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-april-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-mars-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-februar-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2019/nye-markedsforingstillatelser-januar-2019.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-desember-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-november-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-oktober-2018b.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-september-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-august-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-juli-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-juni-2018-b.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-mai-2018-b.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-april-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-mars-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-februar-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2018/nye-markedsforingstillatelser-januar-2018.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-desember-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-november-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-oktober-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-september-2017-002.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-august-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-juli-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-juni-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-mai-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-april-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-mars-2017.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-februar-2017.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2017/nye-markedsforingstillatelser-januar-2017.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-desember-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-november-2016-b.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-oktober-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-september-2016b.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-august-2016b.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-juli-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-juni-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-mai-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-april-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-mars-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-februar-2016b.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2016/nye-markedsforingstillatelser-januar-2016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-desember-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-november-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-oktober-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-september-2015b.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-august-2015b.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-juli-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-juni-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-mai-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-april-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-mars-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-februar-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/liste-over-nye-markedsforingstillatelser/2015/nye-markedsforingstillatelser-januar-2015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/1c60f97e7c7c4ab4868962a44b4f663f/imvixa-vet---key-information---withdrawal-of-the-marketing-authorisation.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/1c60f97e7c7c4ab4868962a44b4f663f/imvixa-vet---applicants-withdrawal-letter.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/soknad-om-markedsforingstillatelse/mailto:vet.felles@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/skjema/godkjenning-av-legemidler/61--notifikasjon-nasjonal-prosedyre.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/endring-av-markedsforingstillatelse/mailto:MT@noma.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/registreringsgebyr/gebyr-2025---human---norsk.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/registreringsgebyr/gebyr-2025---vet---norsk.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/190fd0e6592148ae8404f3c291f87c0d/sunset-clause-2026.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/190fd0e6592148ae8404f3c291f87c0d/sunset-clause-2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/190fd0e6592148ae8404f3c291f87c0d/sunset-clause-2024.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/sunset-clause-2023.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/sunset-clause-2022.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/sunset-clause-2021.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/sunset-clause-2020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/sunset-clause-2019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/sunset-clause-2018.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2017-term-1.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2017-term-2.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2017-term-3.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2016-term-1.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2016-term-2.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2016-term-3.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2015-term-2.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/sunset-clause/2015-term-3.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/mailto:pi@noma.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/skjema/godkjenning-av-legemidler/soknad-om-unntak-fra-avregistrering-i-henhold-til-legemiddelforskriften--8-4-sunset-clause.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/skjema/godkjenning-av-legemidler/soknad-om-unntak-fra-avregistrering-i-samsvar-med-legemiddelforskrifta--8-4-sunset-clause---nynorsk.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/batchspesifikke-unntak/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/batchspesifikke-unntak/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/f39363fcba734f6780bea8cafa3ea52a/veiledning-norsk-engelsk-oversettelse.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/f39363fcba734f6780bea8cafa3ea52a/guidelines-norwegian-english-translations.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/mailto:kodeverk@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/relevant-informasjon-for-soknad-og-oppfolging-av-mt/termer-i-legemiddelgrunndata--standardisering-i-samarbeid-med-brukere/mailto:Kodeverk@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-preparatomtale-og-pakningsvedlegg/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-preparatomtale-og-pakningsvedlegg/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-preparatomtale-og-pakningsvedlegg/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/utforming-av-preparatomtale-og-pakningsvedlegg/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/nyheter/fellesnordiske-pakninger-for-bedre-tilgjengelighet</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/d1b3686c1bd848729febdc05caae970d/dino1.png</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/d1b3686c1bd848729febdc05caae970d/dino2.png</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/d1b3686c1bd848729febdc05caae970d/dino1_landingsside.png</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/d1b3686c1bd848729febdc05caae970d/dino2_landingsside.png</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/d1b3686c1bd848729febdc05caae970d/hai.png</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/d1b3686c1bd848729febdc05caae970d/hai_landingsside.png</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/tel:48098887</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/mailto:dag.jordbru@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/mailto:farmalogg@apotek.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/maler-og-veiledninger-for-produktinformasjon/sporsmal-og-svar-om-unik-identitet-10032017.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/mailto:post@noma.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/mailto:pi@noma.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/tel:22 89 77 00</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/mailto:pi@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/mailto:post@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/produktinformasjon-templater-og-veiledninger/implementeringsfrist-for-merking-og-pakningsvedlegg/tel:(+47)22897700</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/oppdatering-av-produktinformasjon/new-product-information-wording---july-2026_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---june-2026_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---may-2026_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---april-2026_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---march-2026_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/682077f40e3b4077ba5cb01d9e493778/new-product-information-wording---jan-2026_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/~-25_29132-3-25_29132-2-new-product-information-wording---nov-2025_no-39261594_3_0-39277406_1_0.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/7bcdc696568340199a7f97e918cfb905/new-product-information-wording---sep-25_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---may-2025_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/25_09797-2-new-product-information-wording---april-2025_no-38898897_1_0_mld29042025.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---march-2025_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/~-25_04626-2-new-product-information-wording---feb-2025_no-38770360_2_0.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/7bcdc696568340199a7f97e918cfb905/new-product-information-wording---jan-2025_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/oppdatering-av-produktinformasjon/new-product-information-wording---dec-2024_no-final.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---sep-2024_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---july-2024_no-final.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/33f37f78227d486fba8cea3085634d73/~-24_15001-3-new-product-information-wording---june-2024_no-38374930_1_0.doc</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---may-2024_no_updated-27-may_.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/~-24_09694-3-new-product-information-wording---april-2024_no-38279445_1_0.doc</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/0309664795f24c9b9398f6133a51a9c5/new-product-information-wording---march-2024_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/oppdatering-av-produktinformasjon/new-product-information-wording---jan-2024_no.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/oppdatering-av-produktinformasjon/new-product-information-wording---dec-2023_no.doc</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/b30e15ee6af44bfebd8a9234dabca7a9/lesbarhetstest--presentasjon-fra-industrimotet-12052015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a01-klorheksidinglukonat-250319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/natriumfluorid-ao1aa01-1.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-alginsyre-natriumhydrogenkarbonat-aluminiumhydroksid-250319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-famotidin-270319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-famotidin-magnesium-kalsium-270319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-lansoprazol-250319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-natriumalginat-aluminiumhydroksid-natriumhydrogenkarbonat-kalsiumkarbonat-250319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/a02-natriumalginatnatriumhydrogenkarbonatkalsiumkarbonat-120122.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-omeprazol-250319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-pantoprazol-250319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a02-ranitidin-250319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/peppermint-oil---a03-12022019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a03-simethicone_11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a06-bisacodyl-270319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a06-lactulose-280319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/a06-makrogol-3350-180822.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a06-makrogol-4000-07012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/draftvr-sodium-picosulfate-combinations_.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a07-loperamid---27032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/a07-loperamid-simethicon---27032019-rev-03012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a11-vitamin-d3---27032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/a12-kalsium-vitamin-d---27032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/b01-acetylsalisylsyre-19012021.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/b03-ferroglysinsulfatkomplekspentahydrat---17022020-endelig-versjon.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/b03-folsyre---27032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/b03-jernsulfat---270220.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/c05-cinkokain---prednison_110319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/c05-lidokain---hydrokortisonacetat_110319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/d01-amorolfin-1103209.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/d01-ciklopiroks-11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/d01-ekonazolnitrat-11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/c-e/virkestoffrapport_mal_dmp_ren-versjon_cortimyk.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/d01-ketoconazol-11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/d01-klotrimazol-11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/d01-mikonazol-11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/s-t/terbinafin---d01ae15---16.09.2020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/d02-propylenglykol-07012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/d02-carbamide-07012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/karbamid-kombinasjoner-d02-04032021.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/d04-lidokain-07012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/d06-aciclovir-_07012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/aciklovir-hydrokortison-d06-bb53-22062017.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/d06-metronidazol_07012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/d06-penciclovir_07012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/hydrokortison-d07--rev-25022020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/d08ac02-klorheksidin-10-mg-ml.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/d11-minoxidil-29032021.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g01_dekvaliniumklorid_05.06.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g01-ekonazolnitrat_-11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g01-klotrimazol_11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g01-nystatin_04072023.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g03-levonorgestrel-200319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g03-ulipristalacetat-151119.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-a/ostradiol-g03ca03.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g04b-e03_sildenafil_25.06.2026.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/g04b-e08_tadalafil_10.07.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/m01ae01_peroral-ibuprofen_29.10.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/m01-naproksen-120419.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/m02_diklofenak_27.01.2026.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/m02_ibuprofen_18.12.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/n01-lidokain-prilokain_31.05-36031183_1327947_0ktk_uj-003.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/n02-acetylsalisylsyre-150419.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/8b9f3a5bfcc74870886bcc73dc8e042f/n02b-e01_paracetamol_06.05.25.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/n02be51-paracetamol_koffein-14.04.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/8b9f3a5bfcc74870886bcc73dc8e042f/n05_melatonin_09.05.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/virkestoffrapport---valerianarot---no5c-m09.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/n07-nikotin-190319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/p02-mebendazol_11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/p02-pyrvinium_11032019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/permetrin-p03-03052021.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/r01-azelastinhydroklorid110319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/r01-azelastin-flutikason-082021.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/r01-budesonide110319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/r01-fluticasone--rev-14062021.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/r01-ipatropiumbromid-xylometazolinhydroklorid110319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/r01-levokabastinhydroklorid120319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/r01-mometasonfuroat120319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/r01-natriumkromoglikat120319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/r01-oksymetazolinhydroklorid120319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/r01-triamcinolonacetonid120319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/u-z/r01-xylometazolin_dekspantenol120319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/u-z/r01-xylometazolinhydroklorid120319.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/r02-ambroksol-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/r02aa03-amylmetacresol-24-dichlorobenzyl_10.04.26.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/r02-benzydamin-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/r02ax01_flurbiprofen_14.11.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/r02-lidokain_amylmetacresol_diklorobenzylalkohol-13.12.2024.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/r02-lidokain_klorheksidin-12.03.2024.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/r05-acetylcystein-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/ambroksol---r05cb06.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/a-b/r05-bromheksinhydroklorid-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/c-e/efoyblad---r05ca12-12102016.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/r05-guaifenesin-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/r05-noskapinhydroklorid-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/8b9f3a5bfcc74870886bcc73dc8e042f/r05db05-pentoksyverin_08.05.24.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/c-e/r06-cetirizin-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/o-r/ro6ax27-desloratadin-25.02.2026.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/c-e/r06-dimenhydrinat---08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/c-e/r06-ebastin-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/f-j/r06-feksofendindihydroklorid-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/r06-loratadin-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/r06-meklozine-08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/s-t/r06-cyclizine---08012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/s01-ketotifen-09012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/s01-levokabastinhydroklorid-09012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/s01-natriumkromoglikat-09012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/s-t/virkestoffrapport---karbomer---s01xa2---godkjent-25.07.2019.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/v03-kaliumjodid-09012020.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/otc/virkestoffrapporter/k-n/v03_nalokson_20.06.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/om-oss/veiledning-og-rad?WebId=ee9d310e-0b44-4106-a4ea-80c3d1da1659&amp;TermSetId=a67f242d-2a99-4fce-9085-05f119ee0213&amp;TermId=54d62475-d847-4461-8fa6-5898f957b08d</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/reseptfrihet-otc/virkestoffrapporter?WebId=ee9d310e-0b44-4106-a4ea-80c3d1da1659&amp;TermSetId=a67f242d-2a99-4fce-9085-05f119ee0213&amp;TermId=dd54aac3-dcb2-49dc-a5fd-e149966884c7</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/naturlegemidler-og-plantebaserte-legemidler/liste-over-tradisjonelle-og-veletablerte-plantebaserte-legemidler-februar-2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/db90a59875c5421dae1dc9c0054f5b36/homeopatiske-legemidler-tillatt-omsatt-fullstendig-liste-excel-26.02.2025.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/db90a59875c5421dae1dc9c0054f5b36/homeopatiske-legemidler-tillatt-omsatt-fullstendig-liste-excel-26.02.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/db90a59875c5421dae1dc9c0054f5b36/homeopatiske-legemidler-tillatt-omsatt-laveste-fortynningsgrad-februar-2025.pdf.xlsx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/contentassets/db90a59875c5421dae1dc9c0054f5b36/homeopatiske-legemidler-tillatt-omsatt-laveste-fortynningsgrad-26.02.2025.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/homoopatiske-legemidler/merkingsveiledning-september-2015---homoopatika.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/documents/godkjenning-av-legemidler/markedsforingstillatelse/maler-og-veiledninger-for-produktinformasjon/veiledning-ved-forslag-til-navn-pa-legemiddel_clean_-16112015.pdf</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/skjema/godkjenning-av-legemidler/soknad-om-markedsforingstillatelse-for-parallellimportert-legemiddel.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/skjema/godkjenning-av-legemidler/soknad-om-fornyet-markedsforingstillatelse-for-parallellimportert-legemiddel.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/globalassets/skjema/godkjenning-av-legemidler/soknad-om-endring-av-parallellimportert-legemiddel.docx</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/mailto:post@noma.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/mailto:BatchReleaseBloodProd@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
<url><loc>http://www.legemiddelverket.no/godkjenning/godkjenning-og-oppfolging-av-markedsforingstillatelse/annen-informasjon/mailto:BatchReleaseVaccines@dmp.no</loc><changefreq>daily</changefreq><priority>0.00</priority></url>
</urlset>